YHR130C Antibody

What is YHR130C and why are antibodies against it important in research?

YHR130C refers to a specific gene/protein in yeast that has been studied in various cellular function contexts. Antibodies against this protein are essential tools for detecting, quantifying, and studying its localization and interactions. These antibodies enable researchers to track protein expression, perform immunoprecipitation experiments, and investigate protein-protein interactions that may be crucial for understanding fundamental cellular processes. The cold shock protein research methods can be particularly informative when studying YHR130C function, as both involve protein characterization in varying cellular contexts . Western blotting represents one of the primary applications for these antibodies, allowing for protein detection at expected molecular weights with high sensitivity for endogenous levels of expression .

How do I select the appropriate YHR130C antibody format for my research?

Selection depends on your experimental goals. For simple detection via Western blotting, standard monoclonal or polyclonal formats may suffice. For more complex applications like functional studies, consider:

The choice should be guided by whether you need to detect specific modifications, conformations, or protein fragments. Modern synthetic human antibody libraries like HuscI2™ offer advanced options for specialized applications that might be relevant for studying YHR130C interactions .

What experimental controls should I implement when using YHR130C antibodies?

Proper controls are essential for interpreting results correctly. At minimum, include:

• Positive control: Samples known to express YHR130C (e.g., wild-type yeast strains)

• Negative control: Samples with YHR130C knocked out or samples from species without YHR130C homologs

• Secondary antibody-only control: To assess non-specific binding

• Loading control: To normalize protein levels across samples

For more complex experiments, consider knockdown/knockout validation to confirm antibody specificity, as developed for other research antibodies. When performing functional assays, isotype-matched control antibodies should be employed to account for non-specific effects .

How can I map immunogenic epitopes of YHR130C to improve antibody performance?

Epitope mapping is crucial for understanding antibody-antigen interactions and can significantly improve experimental design. A systematic approach involves:

• Generate recombinant fragments of YHR130C protein representing different domains

• Create specific peptide arrays covering the entire YHR130C sequence

• Test antibody binding against these fragments and peptides

• Identify linear epitopes through this binding pattern analysis

This approach has been successfully applied to other proteins like YB-1, where researchers identified distinct epitopes in cold shock and C-terminal domains . Understanding which domains of YHR130C your antibody recognizes can help explain experimental results, especially when studying protein modifications or interactions that might mask the epitope.

What strategies can improve YHR130C antibody specificity and sensitivity?

Enhancing antibody performance requires careful optimization:

Modern antibody discovery platforms integrate multiple requirements and can generate antibodies with specific binding characteristics. For instance, the FlowDesign approach achieved over 60% amino acid recovery rate on CDRH3 regions, demonstrating significant potential for enhancing antibody efficacy in challenging research applications .

How do post-translational modifications of YHR130C affect antibody recognition?

Post-translational modifications (PTMs) can significantly alter epitope accessibility and antibody binding. When studying modified forms of YHR130C:

• Determine if your antibody's epitope contains potential modification sites

• Consider using modification-specific antibodies if you're targeting specific PTM forms

• Compare results from antibodies recognizing different epitopes to build a complete picture

• Use recombinant proteins with and without specific modifications as controls

Research on other proteins shows that protein cleavage patterns and modifications can create complex binding profiles . The spontaneous protein cleavage observed in prokaryotic versus eukaryotic expression systems demonstrates how production methods can affect antibody recognition patterns, something to consider when working with YHR130C antibodies .

What are the optimal conditions for using YHR130C antibodies in Western blotting?

Western blotting protocols should be optimized specifically for YHR130C antibodies:

• Sample preparation: Use appropriate lysis buffers that preserve protein integrity

• Loading amount: Start with standard amounts (20-50 μg of total protein) and adjust based on target abundance

• Antibody dilution: Begin with manufacturer recommendations (typically 1:1000) and optimize as needed

• Incubation conditions: Usually overnight at 4°C or 1-2 hours at room temperature

• Washing stringency: Adjust buffer composition and washing times to minimize background

For detecting YHR130C, which may have an expected molecular weight similar to other research proteins (approximately 80 kDa range), ensure your gel percentage allows proper separation in this molecular weight range . Do not aliquot antibodies unless specifically recommended by the manufacturer, as this can affect consistency and performance .

How should I design experiments to investigate YHR130C protein-protein interactions?

To effectively study protein interactions involving YHR130C:

• Co-immunoprecipitation (Co-IP):

  • Use YHR130C antibodies conjugated to solid supports

  • Include appropriate negative controls (IgG isotype, non-expressing cells)

  • Validate interactions through reciprocal Co-IP with antibodies against suspected interacting partners

• Proximity ligation assays (PLA):

  • Utilize YHR130C antibodies from different species than antibodies against potential interacting partners

  • Carefully optimize antibody concentrations to minimize background

  • Include single antibody controls to establish baseline signal

• FRET/BRET approaches:

  • Design constructs that preserve important domains of YHR130C

  • Ensure fluorophore positioning doesn't interfere with the interaction

Modern screening workflows utilize multiple complementary approaches, similar to the integrated bio-panning strategies used on proteins, peptides, cells, and various complexes in current antibody research platforms .

What techniques can help resolve contradictory results when using different YHR130C antibodies?

When facing inconsistent results:

• Compare epitope locations of different antibodies – they may recognize different protein forms

• Validate results with orthogonal methods (e.g., mass spectrometry)

• Test antibodies on knockout/knockdown samples to confirm specificity

• Consider protein conformation effects – some antibodies may preferentially recognize native vs. denatured forms

Analysis of antibody binding patterns in different experimental contexts has revealed that antibody-protein interactions can be highly context-dependent, resulting in varying recognition patterns across different sample types and experimental conditions . Computational approaches like those used in antibody design can help identify potential structural factors affecting binding .

How can I troubleshoot high background or non-specific binding with YHR130C antibodies?

High background is a common challenge that requires systematic troubleshooting:

For applications requiring extremely high specificity, consider using monoclonal antibodies targeted to unique regions of YHR130C or employ peptide blocking experiments to confirm signal specificity. Modern antibody screening programs use multiple platforms (phage and yeast display) to refine and select high-affinity binders with desired characteristics, including reduced cross-reactivity .

What are the latest approaches for using YHR130C antibodies in functional assays?

Beyond detection, antibodies can be powerful tools for functional studies:

• Intracellular antibody delivery:

  • Cell-penetrating peptide conjugation

  • Electroporation of purified antibodies

  • Expression of intrabodies from transfected constructs

• Signal pathway modulation:

  • Testing antibodies that block or enhance YHR130C interactions

  • Monitoring downstream effects on known signaling pathways

• Combined approaches:

  • Using antibodies alongside CRISPR-based genetic manipulation

  • Correlating antibody-based detection with functional readouts

Current antibody discovery platforms integrate rigorous functional validation processes, including internalization assays and direct cytotoxicity assays, which can be adapted for YHR130C research . The combination of structural and sequence optimization approaches, as demonstrated by recent antibody design algorithms, offers opportunities for developing highly specific functional antibodies .

How do different expression systems affect the production and recognition of YHR130C for antibody development?

The choice of expression system significantly impacts antibody development:

Research on other proteins has shown significant differences in antibody recognition between prokaryotic and eukaryotic expression systems. With prokaryotic systems often showing more complex binding patterns due to protein cleavage . Since YHR130C is a yeast protein, expressing it in yeast systems might provide the most representative form for antibody development or testing.

How are computational methods improving antibody design for targets like YHR130C?

Computational approaches are revolutionizing antibody development:

• Structure-based design:

  • Models like FlowDesign utilize prior distributions from sequence-structure joint distributions

  • Achieve higher sequence recovery rates (up to 15% improvement over random initialization)

  • Generate antibodies with lower energy and more stable binding

• Machine learning approaches:

  • AI-powered phage and yeast display technologies enhance screening workflows

  • Computational models predict antibody-antigen interactions with increasing accuracy

  • Combined sequence-structure co-design outperforms traditional methods

Recent advances have demonstrated that computational methods can simultaneously design all CDRs in both heavy and light chains, achieving amino acid recovery rates exceeding 60% for CDRH3 regions when selecting the top 1% of designed antibodies based on energy calculations .

What emerging applications might YHR130C antibodies have in systems biology research?

As systems biology continues to evolve, YHR130C antibodies could find application in:

• Multi-omics integration:

  • Correlating protein detection with transcriptomic and metabolomic data

  • Mapping protein interaction networks in different cellular states

• Single-cell antibody-based technologies:

  • Combining antibody detection with single-cell RNA sequencing

  • Spatial transcriptomics with antibody validation

• Dynamic systems analysis:

  • Using antibodies to track YHR130C localization and modification changes over time

  • Correlating with functional outputs in response to varied stimuli

The PLAbDab (Patent and Literature Antibody Database) represents a valuable resource for such studies, providing access to extensive functional characterizations of antibodies that could inform YHR130C research approaches . The steady growth in antibody sequences available through such resources (between 10,000-30,000 new sequences annually) enhances the potential for developing specialized research tools .